January 22, 2020
4 min read
This article is more than 5 years old. Information may no longer be current.
CRC surveillance may be unnecessary after polypectomy in some patients
Patients at low and intermediate risk for colorectal cancer may not require postpolypectomy surveillance, according to research published in Gut.
Amanda J. Cross, PhD, of the department of surgery and cancer at Imperial College London, and colleagues wrote that current guidelines may put a burden on colonoscopy resources.
“Revision of the guidelines is required to minimize unnecessary colonoscopies while ensuring that patients at increased CRC risk receive surveillance,” they wrote. “We aimed to identify patient subgroups who could safely forgo surveillance or receive less than currently recommended.”
Researchers conducted a retrospective study comprising 28,972 patients who underwent colonoscopy with adenoma removal and a median follow-up of 9.3 years. They estimated the effect of surveillance on CRC incidence after adjusting for patient characteristics and other factors.
In the study cohort, investigators classified 14,401 patients as low risk (50%), 11,852 as intermediate risk (41%) and 2,719 as high risk (9%). They reported CRC incidences of 140 per 100,00 person-years (95% CI, 122-162), 221 per 100,000 person-years (95% CI, 195-251) and 366 per 100,000 person-years (95% CI, 295-453) in the three groups, respectively.
Additionally, Cross and colleagues found that CRC incidence was lower with a single surveillance visit than with none in the low- (HR = 0.56; 95% CI, 0.39-0.8), intermediate- (HR = 0.59; 95% CI, 0.43-0.81) and high-risk groups (HR = 0.49; 95% CI, 0.29-0.82).
Compared with the general population, CRC incidence without surveillance was similar among the low- (standardized incidence ratio [SIR] = 0.86; 95% CI, 0.73-1.02) and intermediate- (SIR = 1.16; 95% CI, 0.97-1.37) risk groups, whereas it was higher among patients with higher risk (SIR = 1.91; 95% CI, 1.39-2.56).
Cross and colleagues wrote that low-risk patients and intermediate-risk patients without high-grade dysplasia or proximal polyps do not remain at increased CRC risk after a complete baseline colonoscopy and polypectomy.
“Surveillance is probably not necessary for these patients and routine screening would suffice, although patients should be reminded to contact their general practitioner if lower gastrointestinal symptoms occur,” they wrote. “Conversely, surveillance is warranted for high-risk patients, and intermediate-risk patients without a complete baseline colonoscopy or with high-grade dysplasia or proximal polyps, whose risk was higher than in the general population before surveillance.” – by Alex Young
Disclosures: Cross reports she receives funding from the National Institute for Health Research Health Technology Assessment, the Bobby Moore Fund for Cancer Research UK and the Cancer Research UK Population Research Committee Program Award. Please see the study for all other authors’ relevant financial disclosures.
Perspective
Back to Top
This important study from the UK looks at the impact of polypectomy on future risk of colorectal cancer and the impact of follow up surveillance on that risk. It adds evidence to support the stratification of patients with adenomatous polyps into lower and higher risk groups for future CRC based upon their baseline polyp characteristics. We’ve been stratifying patients into low and high-risk groups in the United States for decades. Europeans stratify their patients into three slightly different groups: low, intermediate and high.
The study is retrospective, with its inherent limitations, but demonstrates low-risk patients (with 1-2 adenomas, < 10 mm in size, without any villous features, or proximal polyps) can have a de-escalation in colonoscopy use after baseline polyp removal. The incidence of CRC after polypectomy and without follow up surveillance was 50% lower than the general population incidence. These data suggest these individuals are safe to return to average risk colorectal screening which in Europe, is with the use of fecal immunochemical testing. In intermediate-risk patients (those with 3-4 adenomas, < 10 mm in size or 1-2 adenomas with one or more at least 10 mm in size , who have undergone complete colonoscopy, with adequate bowel preparation, and no proximal polyps or an adenoma with high grade dysplasia, or adenoma greater than 20 mm in size) had the same risk for CRC as the general population without repeat colonoscopy and lower than the general population risk with one surveillance colonoscopy. The subset of those patients with unknown or incomplete colonoscopy, inadequate bowel preparation, proximal polyps or adenomas with high grade dysplasia or at least 20 mm in size, had a higher than population risk for CRC without surveillance but decreased to population risk after one surveillance exam.
High risk patients (with five or more adenomas or three or more adenomas including one of at least 10 mm in size, with incomplete exams or completeness unknown, or adenomas with high grade dysplasia) stayed at a higher than population risk for CRC until after a second surveillance exam. This supports that the high-risk population requires ongoing surveillance, while the intermediate risk group benefits from one post polypectomy surveillance exam.
The study is reassuring, and supports emerging data showing the very low risk for CRC in the lowest risk patients. It expands our knowledge of a lower than previously thought risk in individuals with 3-4 small adenomas. This data supports the new post-polypectomy guidelines by the US Multi-Society Task Force recommendations lengthening the interval in patients with 1-2 small tubular adenomas to 7-10 years, and to 3-5 years in individuals with 3-4 small, tubular adenomas. Accumulating more data is important so we can be prudent and judicious in our use of colonoscopy resources, saving the exam for those most likely to benefit: individuals who have never been screened, those who have high-risk polyp features, and those with a familial or genetic cause of CRC.
Carol A. Burke, MD
Vice Chair, Department of Gastroenterology, Hepatology and Nutrition
Cleveland Clinic
Disclosures: Burke reports she is a member of the U.S. Multi Society Task Force.
Published by: